ANNAPOLIS, Md., June 23, 2016 /PRNewswire/ -- PharmAthene,
Inc. (NYSE MKT: PIP), a biodefense company developing medical
countermeasures against anthrax, today announced that it is set to
join the broad-market Russell 3000® Index at the
conclusion of the Russell U.S. Indexes annual reconstitution,
effective after the U.S. market opens on June 27.
Annual reconstitution of the Russell U.S. indexes captures the
4,000 largest U.S. stocks as of the end of May, ranking them by
total market capitalization. Membership in the U.S. all-cap Russell
3000® Index, which remains in place for one year,
means automatic inclusion in the large-cap Russell
1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and
value style indexes. FTSE Russell determines membership for its
Russell indexes by objective, market capitalization rankings and
style attributes.
Indexes provided by FTSE Russell, a leading global index
provider, are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Approximately $6 trillion
in assets are benchmarked against the Russell U.S. indexes.
About PharmAthene
PharmAthene is a biodefense company engaged in the development
of next generation medical countermeasures against biological
threats. The Company's development portfolio includes two next
generation Anthrax vaccines that are intended to improve protection
while having favorable dosage and storage requirements compared to
other Anthrax vaccines.
About FTSE Russell
FTSE Russell is a global index leader and data provider that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of
indexes that measure and benchmark markets and asset classes in
more than 70 countries, covering 98% of the investable market
globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$10 trillion is currently benchmarked
to FTSE Russell indexes. For over 30 years, leading asset owners,
asset managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance, and embraces the IOSCO principles.
FTSE Russell is also focused on index innovation and client
collaboration as it seeks to enhance the breadth, depth and reach
of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group. For
more information, visit www.ftserussell.com.
Forward-Looking Statement Disclaimer
Except for the historical information presented herein, matters
discussed may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that are subject to certain risks and uncertainties that could
cause actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including
statements preceded by, followed by, or that include the
words "potential"; "believe"; "anticipate"; "intend"; "plan";
"expect"; "estimate"; "could"; "may"; "should"; "will"; "project";
"potential"; or similar statements are forward-looking statements.
Risks and uncertainties include risks associated with our ability
to successfully develop next generation medical countermeasures
against biological threats; the ability of our two next generation
anthrax vaccines to improve protection while having favorable
dosage and storage requirements compared to other anthrax vaccines;
and other risks detailed from time to time in PharmAthene's Forms
10-K and 10-Q under the caption "Risk Factors" and in its other
reports filed with the U.S. Securities and Exchange Commission.
PharmAthene disclaims any intent or obligation to update these
forward-looking statements other than as required by law.
Copies of PharmAthene's public disclosure filings are available
on our website under the investor relations tab at
www.PharmAthene.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pharmathene-to-join-russell-3000-and-global-indexes-300289568.html
SOURCE PharmAthene, Inc.